Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome

Andrew B. Song, Rahul Sakhuja, Nancy M. Gracin, Ronald Weinger, Raj S. Kasthuri, Hanny Al-Samkari

Blood Adv (2021) 5 (19): 3850–3854.

https://doi.org/10.1182/bloodadvances.2021004810

Published: 2021

Journal Articles

Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children

Laura Avila, Nour Amiri, Riddhita De, Jennifer Vincelli, Eleanor Pullenayegum, Suzan Williams, Leonardo R. Brandão

Blood Adv (2021) 5 (19): 3737–3747.

https://doi.org/10.1182/bloodadvances.2021004727

Published: 2021

Includes: Supplemental data

Journal Articles

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America

Ignacio Neumann, Ariel Izcovich, Ricardo Aguilar, Guillermo León Basantes, Patricia Casais, Cecilia C. Colorio, María Cecilia Guillermo Esposito, Pedro P. García Lázaro, Luis A. Meillon-García, Jaime Pereira, Suely Meireles Rezende, Juan Carlos Serrano, Mario L. Tejerina Valle, Felipe Vera, Lorena Karzulovic, Gabriel Rada, Holger Schünemann

Blood Adv (2021) 5 (15): 3032–3046.

https://doi.org/10.1182/bloodadvances.2021004267

Published: 2021

Includes: Supplemental data

Journal Articles

Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis

Damon E. Houghton, Henny Heisler Billett, Manila Gaddh, Oluwatomiloba Onadeko, Gemlyn George, Tzu-Fei Wang, Thein H. Oo, Mingen Feng, Mahua Dasgupta, Michael Jaglal, Michael B. Streiff, Pippa Simpson, Radhika Gali, Lisa Baumann Kreuziger

Blood Adv (2021) 5 (14): 2807–2812.

https://doi.org/10.1182/bloodadvances.2021004698

Published: 2021

Includes: Supplemental data

Journal Articles

Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism

Blood Adv (2021) 5 (8): 2237–2244.

https://doi.org/10.1182/bloodadvances.2020002398

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients

Melissa Yan, Ryan Kieser, Carol C. Wu, Wei Qiao, Cristhiam M. Rojas-Hernandez

Blood Adv (2021) 5 (4): 1050–1058.

https://doi.org/10.1182/bloodadvances.2020003136

Published: 2021

Journal Articles

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Blood Adv (2021) 5 (3): 872–888.

https://doi.org/10.1182/bloodadvances.2020003763

Published: 2021

Includes: Supplemental data

Journal Articles

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Nathan T. Connell, Veronica H. Flood, Romina Brignardello-Petersen, Rezan Abdul-Kadir, Alice Arapshian, Susie Couper, Jean M. Grow, Peter Kouides, Michael Laffan, Michelle Lavin, Frank W. G. Leebeek, Sarah H. O’Brien, Margareth C. Ozelo, Alberto Tosetto, Angela C. Weyand, Paula D. James, Mohamad A. Kalot, Nedaa Husainat, Reem A. Mustafa

Blood Adv (2021) 5 (1): 301–325.

https://doi.org/10.1182/bloodadvances.2020003264

Published: 2021

Includes: Supplemental data

Journal Articles

Systems-based hematology: highlighting successes and next steps

Jori E. May, Patrick C. Irelan, Kailee Boedeker, Emily Cahill, Steven Fein, David A. Garcia, Lisa K. Hicks, Janice Lawson, Ming Y. Lim, Colleen T. Morton, Anita Rajasekhar, Satish Shanbhag, Marc S. Zumberg, Robert M. Plovnick, Nathan T. Connell

Blood Adv (2020) 4 (18): 4574–4583.

https://doi.org/10.1182/bloodadvances.2020002947

Published: 2020

Journal Articles

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism

Olivia S. Costa, Christine G. Kohn, Nicole M. Kuderer, Gary H. Lyman, Thomas J. Bunz, Craig I. Coleman

Blood Adv (2020) 4 (17): 4045–4051.

https://doi.org/10.1182/bloodadvances.2020002242

Published: 2020

Journal Articles

Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis

Synne G. Fronas, Anders E. A. Dahm, Hilde S. Wik, Camilla T. Jørgensen, Jostein Gleditsch, Nezar Raouf, René Holst, Frederikus A. Klok, Waleed Ghanima

Blood Adv (2020) 4 (11): 2468–2476.

https://doi.org/10.1182/bloodadvances.2020001556

Published: 2020

Journal Articles

Outcomes associated with apixaban vs warfarin in patients with renal dysfunction

Claudia Hanni, Elizabeth Petrovitch, Mona Ali, Whitney Gibson, Christopher Giuliano, Jenna Holzhausen, Charles Makowski, Amy Pallisco, Nisha Patel, Denise Sutter, Long To, Raymond Yost

Blood Adv (2020) 4 (11): 2366–2371.

https://doi.org/10.1182/bloodadvances.2019000972

Published: 2020

Journal Articles

Lee AYY. The changing landscape of anticoagulation in cancer-associated thrombosis. Blood Adv. 2020;4(5):969.

Blood Adv (2020) 4 (7): 1221.

https://doi.org/10.1182/bloodadvances.2020001873

Published: 2020

Journal Articles

The changing landscape of anticoagulation in cancer-associated thrombosis

Agnes Y. Y. Lee

Blood Adv (2020) 4 (5): 969.

https://doi.org/10.1182/bloodadvances.2019000842

Published: 2020

Includes: Supplemental data

Journal Articles

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana S. Mathur, Janice Castillo, Mark Crowther, John T. Curnutte

Blood Adv (2020) 4 (4): 728–739.

https://doi.org/10.1182/bloodadvances.2019000885

Published: 2020

Includes: Supplemental data

Journal Articles

American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease

Robert I. Liem, Sophie Lanzkron, Thomas D. Coates, Laura DeCastro, Ankit A. Desai, Kenneth I. Ataga, Robyn T. Cohen, Johnson Haynes, Jr, Ifeyinwa Osunkwo, Jeffrey D. Lebensburger, James P. Lash, Theodore Wun, Madeleine Verhovsek, Elodie Ontala, Rae Blaylark, Fares Alahdab, Abdulrahman Katabi, Reem A. Mustafa

Blood Adv (2019) 3 (23): 3867–3897.

https://doi.org/10.1182/bloodadvances.2019000916

Published: 2019

Includes: Supplemental data

Journal Articles

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

Hanny Al-Samkari, Jean M. Connors

Blood Adv (2019) 3 (22): 3770–3779.

https://doi.org/10.1182/bloodadvances.2019000369

Published: 2019

Journal Articles

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Miney Paquette, Daniel M. Witt, Anne Holbrook, Jane Skov, Jack Ansell, Holger J. Schünemann, Wojtek Wiercioch, Robby Nieuwlaat

Blood Adv (2019) 3 (10): 1638–1646.

https://doi.org/10.1182/bloodadvances.2019000067

Published: 2019

Includes: Supplemental data

Journal Articles

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis

Rasha Khatib, Maja Ludwikowska, Daniel M. Witt, Jack Ansell, Nathan P. Clark, Anne Holbrook, Wojtek Wiercioch, Holger Schünemann, Robby Nieuwlaat

Blood Adv (2019) 3 (5): 789–796.

https://doi.org/10.1182/bloodadvances.2018025163

Published: 2019

Includes: Supplemental data

Journal Articles

American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism

Blood Adv (2018) 2 (22): 3292–3316.

https://doi.org/10.1182/bloodadvances.2018024786

Published: 2018

Includes: Supplemental data

NARROW

Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome

Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America

Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis

Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism

Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

Systems-based hematology: highlighting successes and next steps

Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism

Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis

Outcomes associated with apixaban vs warfarin in patients with renal dysfunction

Lee AYY. The changing landscape of anticoagulation in cancer-associated thrombosis. Blood Adv. 2020;4(5):969.

The changing landscape of anticoagulation in cancer-associated thrombosis

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation

Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis

American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only